SERUM LEVELS OF SPECIFIC MATRIX METALLOPROTEINASES AND CYR-61 IN WOMEN WITH BREAST CANCER

Abstract

The article presents a study investigating the role of serum matrix metalloproteinase-7 (MMP7), MMP-9, and cysteine-rich angiogenic inducer 61 (CYR61) in the early diagnosis of breast cancer (BC). The study included results from 74 women aged 30-51 years who visited the National Oncology Centre in 2023-2024 and were diagnosed with BC. The control group consisted of results from 15 healthy women aged 25-38 years. The biotypes of BC were determined using histochemical analysis methods; results showed that 8 women had a 'triple-negative' phenotype, 33 women had Her2-positive hypersecretion, and 33 women had Her2-negative BC. The control group results were compared with both the overall results of all women with BC and the indicators of various subgroups according to biotypes. According to the study results, no statistically significant differences were found in the levels of the studied biomarkers among Her2-positive, Her2-negative, and triple-negative BC subgroups. However, a statistically significant difference was identified in MMP-9 and CYR-61 levels between the overall BC group and the control group (p<0.001). The study demonstrated that there are no significant differences in serum biomarker levels between BC biotypes depending on Her2 secretion. However, the serum MMP-9 level can be used as a significant laboratory biomarker for the diagnosis of BC, regardless of biotype.